|
BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at Bank of America Securities 2008 Healthcare Conference
Franklin, Tenn. – May 8, 2008 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Larry Bullock, CFO, will provide an update of corporate activities at the Bank of America Securities 2008 Healthcare Conference. The presentation will take place in Ballroom 2 of the Four Seasons Hotel in Las Vegas on Tuesday, May 13 at 5:20 p.m. PDT. A live audio webcast of the presentation will be available at http://www.veracast.com/webcasts/bas/healthcare08/id41114298.cfm and on the Company's website at www.biomimetics.com. The webcast will be accessible for a period of at least 30 days. About BioMimetic Therapeutics BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA in 2005 for its first product, GEM 21S, for regeneration of bone and periodontal tissue loss resulting from periodontal disease. Currently, the Company has clinical trials ongoing with its product candidates GEM OS1 and GEM OS2 in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist. The Company's product and lead product candidates all combine recombinant human platelet derived growth factor (rhPDGF-BB) with tissue specific scaffolds to actively stimulate tissue healing and regeneration. GEM 21S® is a registered trademark of Luitpold Pharmaceuticals, Inc., who owns and markets that product through its Osteohealth Company division. For further information, visit www.biomimetics.com or contact Kearstin Patterson, corporate communications, at 615-236-4419. ### |